Zobrazeno 1 - 10
of 56
pro vyhledávání: '"John P. Feighner"'
Autor:
M. Gutierrez, John P. Feighner, Joseph J. Hlavka, Gabriela Nicolau, S. Ciric, J. Freed, R. Stout
Publikováno v:
Biopharmaceutics & Drug Disposition. 26:379-385
The purpose of this study was to evaluate the safety and pharmacokinetics of nemifitide, a synthetic antidepressant pentapeptide, following its subcutaneous (s.c.) administration by standard needle injection or by a needle-free (Biojecttrade mark) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1557811b0159e6286428507ce55b41c2
https://doi.org/10.1002/bdd.470
https://doi.org/10.1002/bdd.470
Autor:
Gabriela Nicolau, John P. Feighner, Abajian Henry B, Joseph J. Hlavka, George Tonelli, Jeffrey S. Freed, Lev Sverdlov
Publikováno v:
The International Journal of Neuropsychopharmacology. 6:207-213
Data from two Phase 2 clinical studies with nemifitide, a novel pentapeptide antidepressant, were evaluated. The initial double-blind, placebo-controlled study was performed on outpatients with DSM-IV criteria for major depressive disorder. An open-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a41db90c2e64571a6bcaae669a6a9d
https://doi.org/10.1017/s1461145703003481
https://doi.org/10.1017/s1461145703003481
Autor:
Joseph J. Hlavka, John P. Feighner, Lev Sverdlov, Nadia Cardillo Marricco, Abajian Henry B, Gabriela Nicolau, Carlo Di Spirito, George Tonelli, John Morrison, George Faria
Publikováno v:
Biopharmaceutics & Drug Disposition. 23:33-39
Nemifitide (4-fluoro-L-phenylalanyl-trans-4-hydroxy-L-prolyl-L-arginylglycyl-L-tryptophanamide ditrifluoroacetate) is a novel antidepressant, currently in phase 2/3 clinical trials. The purpose of our phase 1 clinical trials (conducted over a three y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72cbde9cf5f5807012f9c994331d5701
https://doi.org/10.1002/bdd.290
https://doi.org/10.1002/bdd.290
Publikováno v:
The International Journal of Neuropsychopharmacology. 3:237-242
Cluster analysis was used to evaluate the data from a placebo-controlled, double-blind clinical trial with a new pentapeptide antidepressant (INN 00835) in major depression. The objective of this paper is to examine the effect of separating the study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781447c403996bc2f2fcd741377e4912
https://doi.org/10.1017/s1461145700002017
https://doi.org/10.1017/s1461145700002017
This book is being published as we mark the end of the first 50 years of the modern antidepressant era. This era began with the chance discovery that tri- clic antidepressants and monoamine oxidase inhibitors had antidepressant p- perties. That disco
Autor:
Angela Williams, Raymond G. Hill, Guanghan Liu, Margaret A. Cascieri, John J. Sramek, John P. Feighner, Gary G. Chicchi, Ram K. Shrivastava, Malcolm MacCoss, Edward M. Scolnick, Duane B. Snavely, Emma J. Carlson, Louise Hewson, Christopher John Swain, Jeffrey J. Hale, Sharon Sadowski, N.R. Cutler, David D. Smith, Nadia M.J. Rupniak, Franz Hefti, Timothy Harrison, Edwina Wyatt-Knowles, Sander G. Mills, Scott A. Reines, Richard Hargreaves, John Carman, Mark S. Kramer
Publikováno v:
Science. 281:1640-1645
The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P antagonists might have psychotherapeutic properties. Like clinically used antidepressant and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::888508e4bee9b37a82f2f5da6928e9e3
https://doi.org/10.1126/science.281.5383.1640
https://doi.org/10.1126/science.281.5383.1640
Autor:
William F. Boyer, John P. Feighner
Publikováno v:
Depression. 2:32-35
Many authorities recommend a 6-week trial of an antidepressant before deciding whether the patient will have a favorable response. However, this length of time is frequently impractical, especially for hospitalized patients. Some data suggests that u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bba55ee3ab5e12c6321dbba26592fa17
https://doi.org/10.1002/depr.3050020104
https://doi.org/10.1002/depr.3050020104
Autor:
John P. Feighner
Publikováno v:
Nordic Journal of Psychiatry. 46:7-16
The SSRIs are a new class of effective antidepressant agents which have proven efficacy in a wide range of psychiatric applications. They are as effective as the tricyclic antidepressants and are better tolerated. The SSRIs are safe in overdose and h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4535839f225fac91e6973b0b5d8ae78b
https://doi.org/10.3109/08039489209101155
https://doi.org/10.3109/08039489209101155